MARGINAL ZONE LYMPHOMA

This early-phase trial tested a new drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to other treatments. The main goals were to find a safe dose and check for side effects. The study was completed, but results are no…

This study tested an oral drug called LOXO-305 (pirtobrutinib) in 803 people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other non-Hodgkin lymphomas whose cancer had stopped responding to or could not tolerate standard treatments. The goal was to find the be…

This study tested a new drug called BGB-10188, alone or combined with other cancer drugs, in 97 people with certain blood cancers (like lymphoma and leukemia) or advanced solid tumors. The main goals were to find safe doses and check for side effects. The trial was completed, but…

This study tested a drug called zanubrutinib in 96 people with certain types of B-cell lymphoma who had severe side effects from similar drugs (ibrutinib or acalabrutinib). The goal was to see if zanubrutinib caused fewer or milder side effects while still controlling the cancer.…

This study looked at a new way to do bone marrow transplants for people with blood cancers like leukemia and lymphoma who don't have a perfectly matched donor. Instead of using a standard drug after transplant, doctors tested a different drug called bendamustine to see if it coul…

This study tested a new treatment called axicabtagene ciloleucel (a CAR T-cell therapy) in 159 adults with follicular or marginal zone lymphoma that had come back or stopped responding to at least two prior treatments. The therapy works by reprogramming a patient's own immune cel…

This early-stage study tested a new drug called PRT2527, alone or combined with other medicines (zanubrutinib or venetoclax), in 86 people with blood cancers that returned or didn't respond to standard treatments. The main goals were to check safety, find the best dose, and see i…

This study tested a combination of drugs called VR-CAP as a first treatment for people with marginal zone lymphoma, a rare blood cancer. 26 patients received the therapy to see how well it controlled the disease over two years. The goal was to measure how long patients lived with…

This study tested a combination of three targeted antibodies (mosunetuzumab, polatuzumab vedotin, and obinutuzumab) in 42 people with untreated slow-growing B-cell non-Hodgkin lymphoma. The goal was to see how many patients achieve a complete response (no cancer detectable). The …